Anterix authorizes $250M stock buyback plan
Anterix Inc. authorized a new common stock repurchase program of up to $250 million running through September 22, 2029.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Anterix Inc. (ATEX) announced that its Board of Directors authorized a new share repurchase program effective September 22, 2026, following the expiration of its prior program on September 21, 2026. Under this program, the company may repurchase up to $250,000,000 of its common stock on or before September 22, 2029.
The company may buy back shares on the open market and through privately negotiated transactions, potentially using Rule 10b5-1 trading plans. The timing and amount of repurchases will depend on business and market conditions and other strategic factors, and the program can be suspended, discontinued, or modified at any time.
Positive
- Board authorized a substantial $250,000,000 common stock repurchase program running through September 22, 2029, providing flexibility for capital return.
Negative
- None.
Filing Explained
The authorized buyback provides capacity of up to
8-K Event Classification
Key Figures
Key Terms
privately negotiated transactions financial
Rule 10b5-1 trading plans regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Is Anterix required to repurchase a specific amount of stock under this program?
AI-generated analysis. How Rhea-AI works. Not financial advice.